# BC Provincial Antimicrobial Clinical Expert (PACE) Committee
# HEALTH AUTHORITY AND COMMUNITY
# CUMMULATIVE ANTIMICROBIAL SUSCEPTIBILITY 2024 SNAPSHOT

BC Health Authorities and community laboratories collaborated to produce this bacterial and fungal pathogens antimicrobial susceptibility report.

- Report is for surveillance only and not a tool to support decision making for patient care.
- Data are from multiple laboratory sources and may be impacted by inconsistencies in testing procedures and should be interpreted accordingly. Specifically, Interior Health Authority antimicrobial susceptibility testing follows EUCAST guidelines, all other regional Health Authorities and BC LifeLabs follow CLSI guidelines and MIC breakpoints will therefore differ.
- Data displayed are for one year only and do not include trends over time. For in depth historical trends for community AMR isolates, refer to the BC CDC AMR Dashboard

**Table 1. Gram Positive Bacterial Antimicrobial Susceptibilities**

| % Susceptible<br>R= resistant | # of Isolates | Amoxicillin | Ampicillin | Cefazolin | Ceftriaxone | Clindamycin | Cloxacillin | Azithromycin | Linezolid | Gent synergy | Nitrofurantoin[u] | Penicillin | Levofloxacin | Ciprofloxacin[u] | Doxycycline | Trimeth/Sulfa | Vancomycin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***Enterococcus faecalis*** | 18982 | 100 | 100 | R | R | R | R | R | 99 | 84 | 99 | | | 78 | | R | 100 |
| ***Enterococcus faecium*** | 4412 | 15 | 15 | R | R | R | R | R | 99 | 78 | R | | | R | | R | 59 |
| ***Staphylococcus aureus (All)*** | 46064 | | | 76 | | | 76 | | | | | | | | | | |
| ***S. aureus (MRSA)*** | 10017 | R | R | R | R | 77 | R | | 100 | | | | | | 93 | 83 | 100 |
| ***S.aureus (MSSA)*** | 28078 | | | 100 | | 82 | 100 | | 100 | | | | | | 97 | 96 | 100 |
| ***Staph lugdunensis*** | 3081 | | | 95 | | 91 | 95 | | | | | | | | 98 | 100 | 71 |
| ***Staph epidermidis*** | 1937 | | | 42 | | 63 | 42 | | | | | | | | 90 | 62 | 100 |
| ***Streptococcus pneumoniae*** | 1527 | 100 | 100 | | 99 | | | 68 | | | | 73 | 100 | | | 75 | |
| ***Strep agalactiae*** (Group B) | 3438 | 100 | 100 | 100 | | 59 | | | | | | 100 | | | | | |
| ***Strep pyogenes*** (Group A) | 6599 | 100 | 100 | 100 | 73 | | | 73 | | | | 100 | | | | | |
| ***Strep anginosus group**** | 591 | | | | 100 | | | | | | | 98 | | | | | 100 |
| ***Strep viridans group**** | 246 | | 72 | | 98 | | | | | | | 71 | | | | | 100 |

* *Streptococcus anginosus* group includes: *Streptococcus anginosus, Streptococcus constellatus* and *Streptococcus intermedius*
** *Streptococcus viridans* group includes: *Streptococcus mitis* group, *Streptococcus mutans* group, *Streptococcus salivarius* group and *Streptococcus sanguinis* group

# HEALTH AUTHORITY AND COMMUNITY
# CUMMULATIVE ANTIMICROBIAL SUSCEPTIBILITY 2024 SNAPSHOT

## Table 2. Gram Negative Bacterial Antimicrobial Susceptibilities

| % Susceptible<br>R= resistant | # of Isolates | Ampicillin | Amox/Clav | Cephalexin[U] | Cefazolin | Cefixime | Ceftriaxone | Ceftazidime | Ciprofloxacin | Fosfomycin[U] | Gentamicin | Meropenem | Nitrofurantoin[U] | Pip/Tazo | Tobramycin | Trimeth/Sulfa |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***Citrobacter freundii*** | 1456 | R | R | R | R | R | 62 | 64 | 87 | | 91 | 97 | 93 | 74 | | 84 |
| ***Citrobacter koseri*** | 632 | R | 96 | R | 93 | | 99 | 99 | 100 | | 100 | 100 | 61 | 98 | | 99 |
| ***Klebsiella aerogenes*** | 1180 | R | R | R | R | | 71 | 72 | 95 | | 100 | 99 | 21 | 74 | | 98 |
| ***Enterobacter cloacae*** | 3007 | R | R | R | R | R | 60 | 65 | 93 | | 97 | 98 | 36 | 72 | | 90 |
| ***Escherichia coli*** | 102779 | 62 | 86 | | 78 | 87 | 89 | | 71 | 96 | 92 | 100 | 98 | | | 81 |
| ***Klebsiella oxytoca*** | 3833 | R | 88 | R | 65 | 93 | 93 | | 94 | | 97 | 99 | 85 | | | 92 |
| ***Klebsiella pneumoniae*** | 14707 | R | 91 | R | 88 | 92 | 92 | | 88 | | 97 | 99 | | | | 91 |
| ***Morganella morganii*** | 1173 | R | R | R | R | R | 88 | 89 | 82 | | 91 | 100 | R | 95 | | 84 |
| ***Proteus mirabilis*** | 7301 | 74 | 95 | | 70 | 94 | 94 | | 86 | | 92 | 100 | R | | | 84 |
| ***Serratia marcescens*** | 1193 | R | R | R | R | | 92 | 98 | 95 | | 98 | 99 | R | 92 | | 99 |
| ***Salmonella spp*** | 383 | 91 | | | | | 98 | | 59 | | | | | | | 96 |
| ***Pseudomonas aeruginosa*** | 9645 | R | R | R | R | R | R | 91 | 86 | | | 93 | | 92 | 99 | R |
| ***Acinetobacter baumanni*** | 458 | R | R | R | R | R | R | 85 | 97 | R | 93 | 93 | | 94 | 99 | |

## Table 3. Miscellaneous Bacterial and Yeast Antimicrobial Susceptibilities

| % Susceptible | # of Isolates | Amoxicillin or Ampicillin | Amox/clav | Azithromycin | Ceftriaxone | Cefuroxime | Ciprofloxacin | Clindamycin | Levofloxacin | Meropenem | Metronidazole | Penicillin | Pip/Tazo | Tetracycline | Trimeth/Sulfa | Vancomycin | Fluconazole | Micafungin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***Candida albicans*** | 439 | | | | | | | | | | | | | | | | 98 | 100 |
| ***Bacteroides fragilis*** | 297 | | 85 | | | | | 53 | | 92 | 98 | | 82 | | | | | |
| ***Campylobacter spp*** | 34 | | | 97 | | | 66 | | | | | | | | | | | |
| ***Haemophilus influenzae*** | 1121 | 73 | | | 100 | | | | 100 | | | | | 83 | 59 | | | |
| ***Cutibacterium acnes*** | 85 | | | | 100 | | | 97 | | | | 100 | | | | 100 | | |

*PACE acknowledges the contribution of Dr. Ahmad Aloufi MD to formulation of this report.*